Stock Taper
OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS
NVS
NOVARTIS AG
NYSE
$138.99
▲ UP 1.33% (1.83)

KEY STATISTICS

Market Cap$260.70 B
52w High$170.46
52w Low$121.57
Dividend Yield3.04%
FrequencyAnnual
P/E15.99
Volume2.48M
Shares Out.1.90B

COMPANY

LEADERSHIP

Vasant Narasimhan
CHIEF EXECUTIVE
Vasant Narasimhan

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 7, 1996
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
75,267

PRICE TARGET

Target High$170.00
Target Low$136.00
Target Median$153.00
Target Consensus$153.00

UPCOMING EARNINGS

DateOct 27, 2026
DayTuesday
Rev. Est.$14.61B
OCT
27
TUE

SPLIT RECORD

DATETYPERATIO
2019-04-09Forward279:250
2000-05-11Forward2:1

PRICE

$138.99 ▲ UP 1.33% (+$1.83)
OVERLAYS
$140$140$1419:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM138.99

About Novartis AG

https://www.novartis.com ↗

Novartis AG, headquartered in Basel, Switzerland, develops and markets healthcare products worldwide through its Innovative Medicines and Sandoz segments, offering prescription medicines, biosimilars, generics, and biotech products.

INDUSTRY

Drug Manufacturers - General

A PRODUCT NOVARTIS AG IS KNOWN FOR

Rhapsido® (remibrutinib)
Rhapsido® (remibrutinib)

Rhapsido® is the first approved oral BTK inhibitor for adult chronic spontaneous urticaria patients unresponsive to antihistamines, representing an innovative, growth-driving addition to Novartis's immunology portfolio.

COMPETITORS

COMPETITOR
CLDX COMPARE
LLY COMPARE
REGN COMPARE
SNY COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
63
LISTED HERE
26
RANKED BY POSITION SIZE
FLCO
0.22% · 1.3M
DFIV
0.55% · 888.9K
PPH
9.31% · 674.3K
AVDE
0.48% · 666.9K
AFTY
3.20% · 389.7K
FENI
0.41% · 340.2K
PB
PBPH
3.86% · 282.0K
FVL
0.38% · 216.5K
LCAP
1.05% · 140.2K
IDVO
1.26% · 133.9K
PID
1.71% · 110.1K
QLTI
3.70% · 75.8K
APIE
0.71% · 60.0K
YOKE
2.47% · 41.2K
BINV
0.81% · 31.1K
MBOX
1.97% · 21.9K
KAT
0.42% · 20.5K
SPWO
1.23% · 20.2K
BNDX
0.00% · 20.0K
HIG.TO
5.70% · 19.7K
KOMP
0.05% · 10.0K
MEDX
6.33% · 7.6K
AADR
2.29% · 6.6K
NE
NEWZ
2.86% · 4.1K
DIVD
1.87% · 3.2K
TIIV
1.31% · 3.1K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
4.58%
HOLDERS
2,242
TOP 12 OF 2,242 · RANKED BY POSITION SIZE
Fisher Asset Management, LLC
15.5M sh · $2.43B
Dodge & Cox
10.6M sh · $1.36B
Primecap Management Co/Ca/
9.3M sh · $1.2B
Morgan Stanley
8.9M sh · $1.22B
Dimensional Fund Advisors LP
8.8M sh · $1.13B
Goldman Sachs Group Inc
6.5M sh · $996.81M
Loomis Sayles & Co L P
5.7M sh · $726.47M
Bank Of America Corp /De/
5.0M sh · $758.07M
Ubs AG
4.6M sh · $435.28M
Franklin Resources Inc
4.5M sh · $617.56M
Managed Account Advisors LLC
3.9M sh · $379.5M
Thomaspartners, Inc.
3.8M sh · $310.69M

RATINGS SNAPSHOT

Overall rating: B+

DCFROEROAD/EP/EP/B
Discounted Cash Flow4
Return On Equity5
Return On Assets5
Debt To Equity1
Price To Earnings2
Price To Book1
Overall Score3

TRADES BY CONGRESS

HOUSE TRADES
Lisa C. McClain
Lisa C. McClain
Sale (Full)
2025-10-30
 Lisa McClain
Lisa McClain
Sale (Partial)
2025-09-25
 George Whitesides
George Whitesides
Sale (Full)
2025-03-24
SENATE TRADES
Sheldon Whitehouse
Sheldon Whitehouse
Sale (Partial)
2024-04-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OVERWEIGHT 2
HOLD 1
EQUAL WEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
HSBC HOLD Morgan Stanley OVERWEIGHT Barclays EQUAL WEIGHT JP Morgan OVERWEIGHT

SECTORS PEERS

PEERPRICE
LLY$1142.01COMPARE
JNJ$267.77COMPARE
ABBV$261.60COMPARE
MRK$145.43COMPARE
AZN$163.68COMPARE
GILD$145.14COMPARE
PFE$27.75COMPARE
BMY$64.05COMPARE